425: Helix II Shareholders Approve BridgeBio Oncology Merger
Merger Announcement
Helix Acquisition Corp. II shareholders overwhelmingly approved all proposals for its business combination with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), clearing the path for the merger and domestication.
Summary
- An Extraordinary General Meeting was held on August 4, 2025, with 19,407,670 (82.55%) of issued and outstanding ordinary shares present, constituting a quorum.
- All 8 proposals presented at the meeting, detailed in the definitive proxy statement/prospectus, were approved by shareholders.
- Key approvals include the Business Combination Agreement with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (BBOT), the domestication of Helix to Delaware, and the issuance of new shares.
- Shareholders also approved new organizational documents for the combined entity, including changes to authorized share capital, adoption of an exclusive forum provision, and supermajority vote requirements for certain amendments.
- The BridgeBio Oncology Therapeutics, Inc. 2025 Stock Option and Incentive Plan and the 2025 Employee Stock Purchase Plan were approved.
- The proposed board of directors for the combined company was elected.
- Upon closing of the transaction, the company will be renamed BridgeBio Oncology Therapeutics, Inc. (PubCo).
Sentiment
Score: 8
Explanation: The filing indicates successful shareholder approval of all critical proposals for the business combination, including the merger, domestication, and capital structure changes. This clears the path for the transaction to close and the new entity to begin operations, which is a highly positive development for the company's strategic objectives. The comprehensive approval suggests strong shareholder alignment.
Positives
- All 8 proposals for the business combination were approved by shareholders, indicating strong support for the merger.
- A high quorum of 82.55% of shares present demonstrates significant shareholder engagement.
- Approval of the Business Combination Agreement facilitates the merger with BBOT, advancing Helix's strategic objective.
- The domestication to Delaware and approval of new organizational documents streamline future corporate governance and operations.
- The approval of stock issuance for the merger and PIPE investors secures necessary capital for the combined entity.
- The Incentive Plan and Employee Stock Purchase Plan approvals provide tools for attracting and retaining talent in the new company.
- The election of all proposed directors ensures a stable leadership structure for BridgeBio Oncology Therapeutics, Inc. post-merger.
- The Adjournment Proposal was not required, confirming sufficient votes were secured for all critical approvals without delay.
Risks
- Changes in domestic and foreign business, market, financial, political, and legal conditions.
- Inability of the parties to successfully or timely enter into definitive agreements or consummate the business combination.
- Risk that regulatory approvals are not obtained, are delayed, or are subject to unanticipated conditions (e.g., SEC statements or enforcements relating to SPACs).
- Risk that the approval of Helix shareholders or any other condition to closing is not obtained.
- Failure to realize the anticipated benefits of the business combination.
- Risks relating to any legal proceedings that may be instituted against Helix, the combined company, or others following the announcement.
- Uncertainty of the projected financial information with respect to BBOT and the combined company.
- Risks related to the approval of BBOT's product candidates and the timing of expected regulatory and business milestones.
- Ability to negotiate definitive contractual arrangements with potential customers.
- Impact of competitive product candidates.
- Ability to obtain sufficient supply of materials.
- Global economic and political conditions.
- The effects of competition on BBOT's future business.
- The amount of redemption requests made by Helix's public shareholders.
- Uncertainty regarding outcomes of BBOT's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidates.
- Risks associated with BBOT's efforts to commercialize its product candidates.
- BBOT's ability to maintain its existing agreements with third parties and to negotiate and enter into new definitive agreements on favorable terms, if at all.
- Intellectual property-related claims.
- BBOT's ability to attract and retain qualified personnel.
- BBOT's ability to source the raw materials for its product candidates.
Future Outlook
The combined company, to be renamed BridgeBio Oncology Therapeutics, Inc., anticipates continued progress in product development activities, including the initiation, completion, and data readouts for clinical trials such as ONKORAS-101 and BREAKER-101, and the expected dosing of the first patient with BBO-11818. There are expectations for the potential approval of BBOT's product candidates, growth in market opportunity, and the therapeutic and curative potential of its pipeline. The company also projects its cash runway and expects to achieve financing and other business milestones.
Industry Context
This filing marks a critical milestone in the SPAC merger process, where Helix Acquisition Corp. II, a special purpose acquisition company, is merging with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), a private biotechnology company focused on oncology. This transaction is characteristic of the biotech sector, which often utilizes SPACs to access public markets for capital-intensive drug development. The successful shareholder vote paves the way for the creation of a new publicly traded oncology therapeutics company, aiming to advance its clinical pipeline and bring new treatments to market.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | NA | Eli Wallace, Ph.D. | Upon consummation of Business Combination | Election to new PubCo board |
| Director | NA | Neil Kumar, Ph.D. | Upon consummation of Business Combination | Election to new PubCo board |
| Director | NA | Frank McCormick, Ph.D., F.R.S., D. Sc. | Upon consummation of Business Combination | Election to new PubCo board |
| Director | NA | Praveen Tipirneni, M.D. | Upon consummation of Business Combination | Election to new PubCo board |
| Director | NA | Michelle Doig | Upon consummation of Business Combination | Election to new PubCo board |
| Director | NA | Bihua Chen | Upon consummation of Business Combination | Election to new PubCo board |
| Director | NA | Raymond Kelleher, M.D., Ph.D. | Upon consummation of Business Combination | Election to new PubCo board |
| Director | NA | Jake Bauer, M.B.A. | Upon consummation of Business Combination | Election to new PubCo board |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Domestication | Helix to be de-registered in the Cayman Islands and transferred by way of continuation to Delaware as a corporation. | Upon effectiveness of Domestication | Changes the legal domicile of the company, potentially impacting regulatory oversight and the applicable corporate law framework. |
| Organizational Documents Amendment | The Helix Articles currently in effect will be amended and restated by the proposed new certificate of incorporation (PubCo Charter) and new bylaws (PubCo Bylaws). | Upon effectiveness of Domestication | Establishes the comprehensive governing framework for the combined entity, defining its structure, rights, and responsibilities. |
| Authorized Share Capital Change | Authorized capital stock of Helix will change from 500,000,000 Helix Class A Shares, 50,000,000 Helix Class B Shares, and 5,000,000 preference shares to 500,000,000 shares of PubCo Common Stock and 10,000,000 shares of undesignated preferred stock. | Upon effectiveness of Domestication | Provides the combined company with flexibility for future equity issuances and capital management, aligning with its new operational status. |
| Exclusive Forum Provision | Adoption of Delaware as the exclusive forum for certain stockholder litigation. | Upon effectiveness of Domestication | Centralizes litigation to a specific jurisdiction, potentially reducing legal costs and preventing forum shopping by litigants. |
| Supermajority Vote Requirement | Requires the affirmative vote of at least two-thirds of the outstanding shares of capital stock entitled to vote to adopt, amend, or repeal the PubCo Bylaws, and a majority for PubCo Charter amendments (except where a lower threshold is provided by Delaware General Corporation Law). | Upon effectiveness of Domestication | Increases the difficulty for future amendments to key governance documents, providing greater stability but potentially less flexibility for rapid changes. |
| Director Removal Standard | Permits the removal of a director only for cause and only by the affirmative vote of not less than two-thirds of the outstanding shares entitled to vote at an election of directors, voting together as a single class. | Upon effectiveness of Domestication | Strengthens director tenure and independence, making it harder to remove directors without significant cause and broad shareholder consensus. |
| Action by Written Consent | Requires stockholders to take action at an annual or special meeting and prohibits stockholder action by written consent in lieu of a meeting. | Upon effectiveness of Domestication | Ensures all significant stockholder actions occur at formal meetings, promoting transparency and discussion but potentially slowing down decision-making processes. |
| Corporate Name Change | The corporate name will change from Helix Acquisition Corp. II to BridgeBio Oncology Therapeutics, Inc. | Upon consummation of Business Combination | Reflects the new identity and primary business focus of the combined entity. |
| Perpetual Corporate Existence | Making PubCo's corporate existence perpetual. | Upon consummation of Business Combination | Ensures long-term operational continuity for the combined entity, removing any time-bound limitations on its existence. |
| Blank Check Company Provisions Removal | Removing certain provisions related to Helix's status as a blank check company that will no longer be applicable upon consummation of the Business Combination. | Upon consummation of Business Combination | Aligns the corporate structure and governance with that of an operating company post-merger, reflecting its new business purpose. |
Stakeholder Impact
- Shareholders: The approval of the merger and related proposals allows the transaction to proceed, transforming Helix shares into shares of the new oncology therapeutics company (BridgeBio Oncology Therapeutics, Inc.), providing shareholders with an investment in an operating biotech company.
- Employees: The approval of the 2025 Stock Option and Incentive Plan and the 2025 Employee Stock Purchase Plan provides mechanisms for employee compensation and equity participation in the combined entity, potentially aiding in talent retention and motivation.
- Management: The election of the proposed board of directors ensures a clear leadership structure for the combined company, providing stability and direction for its future operations.
Next Steps
- Consummation of the Business Combination between Helix Acquisition Corp. II and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics).
- Renaming the company to BridgeBio Oncology Therapeutics, Inc. (PubCo).
- Issuance of shares of PubCo Common Stock to Helix shareholders in the Domestication and BBOT stockholders in the merger.
- Issuance of shares of PubCo Common Stock to PIPE Investors in the PIPE Investment.
- Continued product development activities, including clinical trials for ONKORAS-101, BREAKER-101, and BBO-11818.
- Pursuit of potential regulatory approval for BBOT's product candidates.
Key Dates
| Date | Description |
|---|---|
| February 28, 2025 | Original Business Combination Agreement date. |
| June 17, 2025 | Amendment No. 1 to the Business Combination Agreement date. |
| June 30, 2025 | Record date for the Extraordinary General Meeting. |
| July 10, 2025 | Definitive proxy statement/prospectus declared effective by the U.S. Securities and Exchange Commission (SEC). |
| August 4, 2025 | Date of Extraordinary General Meeting and date of report. |
Recommendation
buyThe overwhelming shareholder approval of all proposals for the business combination with BridgeBio Oncology Therapeutics (BBOT) significantly de-risks the merger process for Helix Acquisition Corp. II. This green light allows the transaction to proceed, transforming Helix into a publicly traded oncology therapeutics company with a clear path for its clinical pipeline. The approval of incentive plans and a new board further strengthens the combined entity's operational foundation. While risks inherent to biotech development remain, the successful vote removes a major hurdle, making the combined entity a more attractive investment for those seeking exposure to the oncology sector.
Keywords
SPAC, Merger, Acquisition, Biotechnology, Oncology, SEC Filing, Shareholder Vote, Business Combination, Helix Acquisition Corp. II, TheRas Inc., BridgeBio Oncology Therapeutics, Domestication, Corporate Governance, Clinical Trials, Product Candidates, Nasdaq Listing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.